Prostate cancer decisions — 2025

The appeal of a proposal to reduce the rating for service-connected prostate cancer residuals from 100 percent to 40 percent is dismissed as it was not a final decision.

The Board granted a 60 percent initial rating for prostate cancer residuals and remanded the issue of service connection for additional residuals, including bladder, pelvic, and sacral metastases.

The veteran withdrew his appeals for increased ratings and service connection, resulting in the dismissal of all claims.

The Board granted a 100 percent rating for locally recurrent prostate cancer and special monthly compensation (SMC) at the housebound rate from November 1, 2025.

The Veteran's service-connected disabilities of major depressive disorder and residuals of prostate cancer render him unable to secure or follow a substantially gainful occupation, warranting an earlier effective date for the award of a total disability rating based on individual unemployability (TDIU) from June 17, 2021.

The Board remands the claims for service connection for coronary artery disease, bladder cancer, hypertension, and prostate cancer to correct a duty to assist error regarding the Veteran's asserted in-service exposure to herbicide agents based on the information included in the claims file.

The Veteran is granted a total disability rating based on individual unemployability due to service-connected disabilities, including PTSD, prostate cancer, diabetes mellitus type 2, and erectile dysfunction, effective May 24, 2021.

The Board granted service connection for the cause of the Veteran's death, finding that his prostate cancer and/or bone metastases were at least as likely as not related to his service-connected colon carcinoma and/or in-service exposure to chemicals.

The Board remands the claims for service connection for colon cancer, liver cancer, and prostate cancer due to a pre-decisional duty to assist error.

The Board denied the restoration of a 100 percent rating for prostate cancer but granted a 100 percent rating based on renal dysfunction from September 1, 2024.

The Board granted service connection for prostate cancer residuals and cirrhosis, both presumed to be related to exposure to contaminated water at Camp Lejeune.

The Board remands the claims for service connection for prostate cancer with nocturia and Parkinsonism/Parkinson's disease as the prior medical opinions are found to be inadequate.

The Veteran's service-connected disabilities, including prostate cancer residuals and PTSD, render him unable to secure or follow a substantially gainful occupation. However, an evaluation in excess of 60 percent for his prostate cancer is not warranted.

The Board denied the veteran's claims for earlier effective dates and a compensable rating for hypertension, but granted special monthly compensation (SMC) under 38 U.S.C. § 1114(p).

The appeal was dismissed due to the Veteran's death while it was pending.

The Board denied the veteran's claims for increased ratings and granted effective dates of August 24, 2021, for service connection grants.

The Board granted service connection for various conditions, including hypertension, aortic aneurysm repair with heart disease, peripheral neuropathy, prostate cancer, and erectile dysfunction, effective April 14, 2018.

The Board granted service connection for prostate cancer in remission, resolving reasonable doubt in favor of the Veteran and finding that his condition is related to in-service exposure to asbestos.

The Board remands the claims for service connection for prostate cancer and erectile dysfunction on a basis other than as pursuant to the PACT Act due to an inadequate VA examination.

The Board granted service connection for non-allergic rhinitis, lung nodules, prostate cancer, and diabetes mellitus due to herbicide agent exposure. The claims for an ocular disorder and kidney disease were denied.